The evidence of active RIPK2 in IBC tumor tissues following neoadjuvant chemotherapy (such as treatment with three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide [FEC] followed by three cycles of docetaxel) led us to question if RIPK2 was elevated in IBC patients at diagnosis and then was force-activated following chemotherapy. The gene discussed is RIPK2; the disease is neoplasm.